CRTX - Jasper more than doubles while M&A headlines weekly healthcare performers

While the S&P 500 index added ~1.8% gain over the week, its healthcare constituents underperformed with a ~0.8% rise yet, recording their first weekly gain in more than a month. Dragged down by pharma stocks, the sector became the second-worst performer in the index for another week. M&A deals propelled some of the biggest gainers this week as dealmaking activity in the sector accelerated. However, among stocks with more than $300M market capitalization and over 100K average daily volume over the past five sessions, Jasper Therapeutics (NASDAQ:JSPR) dominated with no impact from M&A. Adding ~106.3% over the week, Jasper (JSPR) jumped nearly a third on Friday, coinciding with an event led by an Oppenheimer analyst, who recently turned bullish on the stock. A deal by Supernus Pharmaceuticals (NASDAQ:SUPN) to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) propelled the latter by ~75.1%, while Protagonist Therapeutics (NASDAQ:PTGX) added ~69.8% after the FDA lifted a clinical hold on its rusfertide clinical studies. Several bullish calls followed and

For further details see:

Jasper more than doubles while M&A headlines weekly healthcare performers